广康生化
(300804)
| 流通市值：11.61亿 | | | 总市值：31.23亿 |
| 流通股本：2750.00万 | | | 总股本：7400.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 151,541,954.01 | 138,964,042.14 | 121,030,292.39 | 220,250,332.06 |
| 应收票据及应收账款 | 217,471,125.53 | 265,304,394.39 | 232,744,298.04 | 229,975,820.15 |
| 其中：应收票据 | 35,339,564.55 | 76,169,460.88 | 35,230,733.78 | 34,746,313.43 |
| 应收账款 | 182,131,560.98 | 189,134,933.51 | 197,513,564.26 | 195,229,506.72 |
| 应收款项融资 | 7,735,634.55 | 3,257,140.14 | 1,236,127.15 | 6,226,299.78 |
| 预付款项 | 21,209,875.23 | 19,763,463 | 11,531,121.23 | 18,074,985.3 |
| 其他应收款合计 | 3,367,720.87 | 1,073,834.31 | 6,258,158.76 | 5,301,669.59 |
| 其中:应收利息 | - | 1,071,791.67 | 860,694.44 | 154,033.33 |
| 存货 | 178,626,542.47 | 149,204,013.65 | 192,834,181.42 | 189,580,244.58 |
| 其他流动资产 | 53,523,236.87 | 215,226,166.44 | 53,660,185.5 | 49,437,295.99 |
| 流动资产平衡项目 | 1,327,083.64 | 0 | 0 | 0 |
| 流动资产合计 | 1,086,819,116.31 | 1,063,088,386.12 | 1,039,294,364.49 | 1,068,846,647.45 |
| 非流动资产: | | | | |
| 固定资产 | 511,218,817.09 | 522,486,043.89 | 494,324,585.69 | 507,368,989.05 |
| 在建工程 | 218,669,526.29 | 206,900,979.85 | 159,272,522.75 | 141,503,543.52 |
| 使用权资产 | 2,219,041.82 | 2,496,422.03 | 2,971,905.35 | 3,298,811.36 |
| 无形资产 | 148,634,315.56 | 149,539,692.79 | 152,430,782.82 | 153,908,983.78 |
| 长期待摊费用 | 5,515,935.56 | 4,762,940.41 | 4,759,285.16 | 5,223,290.57 |
| 递延所得税资产 | 12,055,955.02 | 11,836,305.56 | 8,899,157.37 | 7,285,330.79 |
| 其他非流动资产 | 25,967,604.63 | 24,285,266.01 | 43,375,394.67 | 40,326,203.1 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 924,281,195.97 | 922,307,650.54 | 866,033,633.81 | 858,915,152.17 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,011,100,312.28 | 1,985,396,036.66 | 1,905,327,998.3 | 1,927,761,799.62 |
| 流动负债: | | | | |
| 短期借款 | 175,659,061.71 | 144,041,811.6 | 192,383,421.61 | 214,155,644.72 |
| 应付票据及应付账款 | 202,092,390.04 | 225,899,291.63 | 225,357,238.93 | 245,140,945.37 |
| 其中：应付票据 | 72,985,633.67 | 68,299,838.94 | 110,508,276.7 | 133,484,543.05 |
| 应付账款 | 129,106,756.37 | 157,599,452.69 | 114,848,962.23 | 111,656,402.32 |
| 合同负债 | 10,785,184.7 | 6,521,953.27 | 7,770,916.07 | 5,623,251.82 |
| 应付职工薪酬 | 7,411,086.05 | 12,553,812.05 | 11,035,018.36 | 10,614,033.62 |
| 应交税费 | 6,262,453.33 | 5,420,405.94 | 5,387,454.72 | 3,443,251.76 |
| 其他应付款合计 | 762,619.84 | 1,361,475.46 | 787,024.84 | 1,035,124.7 |
| 一年内到期的非流动负债 | 46,807,553.83 | 46,068,971.4 | 18,391,520.31 | 22,817,179.82 |
| 其他流动负债 | 47,652,099.24 | 79,395,585.91 | 389,382.77 | 508,779.61 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 497,432,448.74 | 521,263,307.26 | 461,501,977.61 | 503,338,211.42 |
| 非流动负债: | | | | |
| 长期借款 | 143,476,785.88 | 111,861,880.03 | 102,496,662.38 | 103,319,338.12 |
| 租赁负债 | 1,452,472.4 | 1,458,559.48 | 1,595,927.21 | 1,397,038.6 |
| 预计负债 | 235,246.01 | - | 266,502.97 | 343,076.64 |
| 递延收益 | 22,662,824.84 | 22,937,753.95 | 22,370,327.72 | 4,095,968.15 |
| 递延所得税负债 | 3,853,249.81 | 4,197,204.97 | 4,811,189.33 | 5,069,076.02 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 171,680,578.94 | 140,455,398.43 | 131,540,609.61 | 114,224,497.53 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 669,113,027.68 | 661,718,705.69 | 593,042,587.22 | 617,562,708.95 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 74,000,000 | 74,000,000 | 74,000,000 | 74,000,000 |
| 资本公积 | 846,554,130.54 | 846,502,638.84 | 846,354,963.6 | 846,207,288.36 |
| 专项储备 | 2,963,984.81 | 1,712,949.25 | 1,291,433.47 | 987,951.85 |
| 盈余公积 | 53,795,999.01 | 53,795,999.01 | 49,011,930.69 | 49,011,930.69 |
| 未分配利润 | 363,710,951.02 | 346,601,423.03 | 340,395,259.97 | 338,663,289.82 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,341,025,065.38 | 1,322,613,010.13 | 1,311,053,587.73 | 1,308,870,460.72 |
| 少数股东权益 | 962,219.22 | 1,064,320.84 | 1,231,823.35 | 1,328,629.95 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,341,987,284.6 | 1,323,677,330.97 | 1,312,285,411.08 | 1,310,199,090.67 |
| 负债和股东权益合计 | 2,011,100,312.28 | 1,985,396,036.66 | 1,905,327,998.3 | 1,927,761,799.62 |
| 公告日期 | 2025-04-18 | 2025-04-18 | 2024-10-25 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |